Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial - Rigby, Mark R; DiMeglio, Linda A; Rendell, Marc S; Felner, Eric I; Dostou, Jean M; Gitelman, Stephen E; Patel, Chetanbabu M; Griffin, Kurt J; Tsalikian, Eva; Gottlieb, Peter A; Greenbaum, Carla J; Sherry, Nicole A; et al. (The lancet. Diabetes & endocrinology, 2013)
Keywords: Adolescent; Adult; Alefacept; Child; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - immunology; Double-Blind Method; Drug Delivery Systems - methods; Endocrinology & Metabolism; Female; Humans; Hypoglycemic Agents - administration & dosage; Immunologic Memory - drug effects; Immunologic Memory - immunology; Male; Other; Recombinant Fusion Proteins - administration & dosage; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Young Adult